Pfizer Inc. (PFE)

34.34
NYSE : Health Technology
Prev Close 35.08
Day Low/High 34.17 / 35.35
52 Wk Low/High 33.97 / 46.47
Avg Volume 24.67M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 194.03B
EPS 1.90
P/E Ratio 15.80
Div & Yield 1.44 (4.01%)

Latest News

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.

Pfizer Invests Half Billion Dollars To Advance State-of-the-Art Gene Therapy Facility In Sanford, North Carolina

Pfizer Invests Half Billion Dollars To Advance State-of-the-Art Gene Therapy Facility In Sanford, North Carolina

Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina.

Teva's Generic EpiPen Jr Is Now Available for $300

Teva's Generic EpiPen Jr Is Now Available for $300

There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #20 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #299 spot.

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.

Pfizer Announces Phase 3 Top-Line Results For Rivipansel In Patients With Sickle Cell Disease Experiencing A Vaso-Occlusive Crisis

Pfizer Announces Phase 3 Top-Line Results For Rivipansel In Patients With Sickle Cell Disease Experiencing A Vaso-Occlusive Crisis

Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints.

Pfizer Announces Closing Of Joint Venture With GlaxoSmithKline To Create A Premier Global Consumer Healthcare Company

Pfizer Announces Closing Of Joint Venture With GlaxoSmithKline To Create A Premier Global Consumer Healthcare Company

Pfizer Inc. (NYSE: PFE) today announced the closing of its joint venture with GlaxoSmithKline plc (NYSE: GSK) to combine the parties' respective consumer healthcare businesses to create the world's largest over-the-counter (OTC) business with robust...

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.

Pfizer Completes Acquisition Of Array Biopharma

Pfizer Completes Acquisition Of Array Biopharma

Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

NEW YORK, July 29, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Pfizer reports earnings and announces a massive tie-up with Mylan, sending shares of the latter shooting higher.

A Look at Mylan's New Post-Merger Management

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

It's Market Madness: Jim Cramer on Earnings Season, Pfizer and Mylan, Starbucks

It's Market Madness: Jim Cramer on Earnings Season, Pfizer and Mylan, Starbucks

Jim Cramer weighs in on Pfizer and Mylan, Starbucks and, of course, the causes for a week of market madness.

Pfizer to Combine Off-Patent Drug Division With Mylan

Pfizer to Combine Off-Patent Drug Division With Mylan

Mylan and Pfizer agreed to combine their off-patent drug businesses in an all-stock deal that will create a new company based in the United States.

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Pfizer is in talks to merge its off-patent drug operation with Mylan.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.

Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call To July 29, 2019 At 10:30 A.m. EDT

Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call To July 29, 2019 At 10:30 A.m. EDT

Due to today's announcement of a proposed transaction between Pfizer and Mylan, Pfizer's second-quarter 2019 earnings conference call with investment analysts has been rescheduled for today, July 29, 2019, at 10:30 a.

PFIZER REPORTS SECOND-QUARTER 2019 RESULTS 

PFIZER REPORTS SECOND-QUARTER 2019 RESULTS 

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2019 and updated certain components of its 2019 financial guidance.

Mylan And Upjohn, A Division Of Pfizer, To Combine, Creating A New Champion For Global Health Uniquely Positioned To Fulfill The World's Need For Medicine

Mylan And Upjohn, A Division Of Pfizer, To Combine, Creating A New Champion For Global Health Uniquely Positioned To Fulfill The World's Need For Medicine

- Delivers enhanced global scale and geographic reach, including leading positions in China and other emerging markets

Mylan Shares Surge Amid Reports of Off-Patent Drug Combination with Pfizer

Mylan Shares Surge Amid Reports of Off-Patent Drug Combination with Pfizer

Mylan shares were indicated sharply higher Monday amid reports the generic drugs group is set to create a separate business with Pfizer for off-patent pharmaceuticals.

Pfizer, Mylan Plan to Combine Generic Drug Business: Reports

Pfizer, Mylan Plan to Combine Generic Drug Business: Reports

Shareholders of Mylan would get around 40% of the newly formed business and Pfizer shareholders would get the remaining 60%, according to Reuters.

Go-Go Growth: Cramer's 'Mad Money' Recap (Tuesday 7/23/19)

Go-Go Growth: Cramer's 'Mad Money' Recap (Tuesday 7/23/19)

Jim Cramer says higher sales, higher prices, and demand from emerging markets seem to be fueling a return to the days of great senior growth stocks.

Pfizer, eBay, Cloudera: 'Mad Money' Lightning Round

Pfizer, eBay, Cloudera: 'Mad Money' Lightning Round

Jim Cramer weighs in on Pfizer, eBay, Cloudera, Cadence Systems, CRISPR Therapeutics, Moderna, Tandem Diabetes Care, and more.

TheStreet Quant Rating: B (Buy)